Form 4 for VRTX Vertex Pharmaceuticals
Accepted 2023-02-16 00:00:00 ET · period of report 2023-02-14 · accession 0001209191-23-010061 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2023-02-16 | 2023-02-14 | VRTX | Tatsis Ourania | EVP, Chief Reg, Quality Off | S - Sale | $298.52 | -320 | 65.7K | -0.5% | -$95.5K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-02-14 | S | D | 135 | $299.60 | 65,496 | D | — | — | (F2) Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. (F5) Open market sales reported on this line occurred at a weighted average price of $299.60 (range $299.19 to $300.16). |
| 2 | Common | Common Stock | 2023-02-14 | S | D | 51 | $300.58 | 65,445 | D | — | — | (F6) Open market sales reported on this line occurred at a weighted average price of $300.58 (range $300.34 to $301.01). (F2) Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. |
| 3 | Common | Common Stock | 2023-02-14 | S | D | 43 | $297.98 | 65,631 | D | — | — | (F4) Open market sales reported on this line occurred at a weighted average price of $297.98 (range $297.50 to $298.48). (F2) Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. |
| 4 | Common | Common Stock | 2023-02-14 | S | D | 20 | $296.48 | 65,674 | D | — | — | |
| 5 | Common | Common Stock | 2023-02-14 | S | D | 71 | $295.89 | 65,694 | D | — | — | (F2) Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. (F3) Open market sales reported on this line occurred at a weighted average price of $295.89 (range $295.36 to $296.32). |